Pharmacology, Toxicology and Pharmaceutical Science
HIV
100%
Disease
28%
Clinical Trial
23%
Isoniazid
20%
Tuberculosis
18%
Rifapentine
17%
Rilpivirine
16%
Cabotegravir
16%
Pharmacokinetics
14%
Human Immunodeficiency Virus Infection
12%
Drug Resistant Tuberculosis
12%
Infection
12%
Human Immunodeficiency Virus 1
12%
Rifampicin
11%
Efavirenz
11%
RNA Directed DNA Polymerase Inhibitor
10%
Lung Tuberculosis
10%
Human Immunodeficiency Virus 1 Infection
8%
Proteinase Inhibitor
8%
Adverse Event
7%
HIV Associated Dementia
7%
Multi-Drug-Resistant Tuberculosis
6%
Prevalence
6%
Gamma Interferon
6%
Latent Tuberculosis
6%
Tuberculostatic Agent
5%
Mixed Infection
5%
Atazanavir
5%
Medicine and Dentistry
Human Immunodeficiency Virus
63%
Antiretroviral Therapy
16%
Tuberculosis
13%
Household
13%
Cabotegravir
13%
Clinical Trial
13%
Infection
12%
Human Immunodeficiency Virus Infection
11%
Disease
11%
Rilpivirine
11%
Human Immunodeficiency Virus 1 Infection
9%
Prophylaxis
9%
Prevalence
7%
Rifampicin
7%
Human Immunodeficiency Virus 1
7%
Drug Resistant Tuberculosis
6%
Diagnosis
6%
Pre-Exposure Prophylaxis
6%
Multidrug Resistant Tuberculosis
6%
Low and Middle Income Countries
6%
Hepatitis C Virus
6%
Tenofovir Alafenamide
6%
Cross Sectional Study
5%
Arm
5%
Lung Tuberculosis
5%
Cell Count
5%
Latent Tuberculosis
5%
Keyphrases
Human Immunodeficiency Virus Type 1 (HIV-1)
16%
AIDS/HIV
12%
People Living with HIV (PLHIV)
10%
Rifapentine
8%
Antiretroviral Therapy
7%
Long-acting Antiretrovirals
6%
Efavirenz
6%
Virological Failure
6%
HIV RNA
5%
Tuberculosis
5%
CD4 Count
5%
Phase II Trial
5%
Rilpivirine
5%
HIV Patients
5%
HIV Infection
5%